EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S‐1 for Resectable Biliary Tract Cancer With FDG ‐ PET ‐Positive Lymph Node Metastasis ( KHBO1201 ): A Multicenter Phase II Trial

Satoshi Ogiso, Etsuro Hatano iD, Satoru Seo, Masashi Kanai, Shogo Kobayashi iD, Hiroshi Wada iD, Hidetoshi Eguchi iD, Tatsuya Higashi, Hiroaki Nagano iD, Tatsuya Ioka

Journal of Hepato-Biliary-Pancreatic Sciences · 2026

DOI: 10.1002/jhbp.70030 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2026. Verfasst von Satoshi Ogiso und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Deoxycytidine, Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the safety and efficacy of neoadjuvant gemcitabine, cisplatin, and S‐1 (GCS) chemotherapy for resectable biliary tract cancer (BTC) and FDG‐PET‐positive lymph nodes in a multicenter phase II study (KHBO1201).

Methods

Patients with resectable BTC (intrahepatic/extrahepatic bile duct, gallbladder, or ampullary cancers) and FDG‐PET‐positive lymph nodes received GCS chemotherapy: gemcitabine/cisplatin on Day 1 and oral S‐1 for 7 days, repeated every 2 weeks for 3–6 cycles. Surgery was planned 4–8 weeks later if the tumor was deemed resectable. The primary endpoint was the curative resection rate. Secondary endpoints were the completion rate, radiological response, radiological/pathological complete response (CR) of FDG‐PET‐positive lymph nodes, and 1‐year survival (UMIN000009831).

Results

Twenty‐five patients were enrolled. Twenty‐three (92%) completed GCS without treatment‐related deaths; grade 3 biliary infection occurred in 8.0%. Curative resection was achieved in 60% with a morbidity rate of 40%. The radiological response rate was 13%, and the radiological and pathological CR rates of FDG‐PET‐positive lymph nodes were 24% and 28%, respectively. The 1‐year survival rate was 75%.

Conclusions

Neoadjuvant GCS chemotherapy is safe, feasible, and potentially effective for resectable BTC with FDG‐PET‐positive lymph nodes. A randomized phase III trial (JCOG1920) is underway to compare neoadjuvant GCS chemotherapy with upfront surgery (jRCTs031200388).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineBiliary Tract NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleGemcitabineNeoadjuvant TherapyMiddle AgedCisplatinAgedLymphatic MetastasisFluorodeoxyglucose F18Drug CombinationsOxonic AcidTegafurPositron-Emission TomographyAdultTreatment OutcomeRadiopharmaceuticalsLymph Nodes

Stichwörter der Autor:innen

biliary tract neoplasmschemotherapylymphatic metastasisneoadjuvant therapypositron‐emission tomography

Substanzen

GemcitabineDeoxycytidineCisplatinFluorodeoxyglucose F18Drug CombinationsOxonic AcidTegafurS 1 (combination)Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Surgery, Kochi Medical School, Nankoku-City, Kochi, Japan.
  • Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
  • Cancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan.
  • Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

ORCID-Profile: Etsuro Hatano, Shogo Kobayashi, Hiroshi Wada, Hidetoshi Eguchi, Hiroaki Nagano

Zitieren

APA

Ogiso, S., Hatano, E., Seo, S., Kanai, M., Kobayashi, S., Wada, H., Eguchi, H., Higashi, T., Nagano, H., & Ioka, T. (2026). Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S‐1 for Resectable Biliary Tract Cancer With FDG ‐ PET ‐Positive Lymph Node Metastasis ( KHBO1201 ): A Multicenter Phase II Trial. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.70030

Vancouver

Ogiso S, Hatano E, Seo S, Kanai M, Kobayashi S, Wada H, et al. Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S‐1 for Resectable Biliary Tract Cancer With FDG ‐ PET ‐Positive Lymph Node Metastasis ( KHBO1201 ): A Multicenter Phase II Trial. Journal of Hepato-Biliary-Pancreatic Sciences. 2026. doi:10.1002/jhbp.70030

BibTeX
@article{Ogiso2026,
  author = {Ogiso, Satoshi and Hatano, Etsuro and Seo, Satoru and Kanai, Masashi and Kobayashi, Shogo and Wada, Hiroshi and Eguchi, Hidetoshi and Higashi, Tatsuya and Nagano, Hiroaki and Ioka, Tatsuya},
  title = {Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S‐1 for Resectable Biliary Tract Cancer With FDG ‐ PET ‐Positive Lymph Node Metastasis ( KHBO1201 ): A Multicenter Phase II Trial},
  journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
  year = {2026},
  doi = {10.1002/jhbp.70030}
}
Kostenlos starten →